141 related articles for article (PubMed ID: 36647834)
1. A phosphorylation switch controls androgen biosynthesis in prostate cancer.
Qiu Y
J Clin Invest; 2023 Jan; 133(2):. PubMed ID: 36647834
[TBL] [Abstract][Full Text] [Related]
2. Intratumoral androgen biosynthesis associated with 3β-hydroxysteroid dehydrogenase 1 promotes resistance to radiotherapy in prostate cancer.
Ganguly S; Lone Z; Muskara A; Imamura J; Hardaway A; Patel M; Berk M; Smile TD; Davicioni E; Stephans KL; Ciezki J; Weight CJ; Gupta S; Reddy CA; Tendulkar RD; Chakraborty AA; Klein EA; Sharifi N; Mian OY
J Clin Invest; 2023 Nov; 133(22):. PubMed ID: 37966114
[TBL] [Abstract][Full Text] [Related]
3. AR Signaling in Prostate Cancer Regulates a Feed-Forward Mechanism of Androgen Synthesis by Way of HSD3B1 Upregulation.
Hettel D; Zhang A; Alyamani M; Berk M; Sharifi N
Endocrinology; 2018 Aug; 159(8):2884-2890. PubMed ID: 29850791
[TBL] [Abstract][Full Text] [Related]
4. BMX controls 3βHSD1 and sex steroid biosynthesis in cancer.
Li X; Berk M; Goins C; Alyamani M; Chung YM; Wang C; Patel M; Rathi N; Zhu Z; Willard B; Stauffer S; Klein E; Sharifi N
J Clin Invest; 2023 Jan; 133(2):. PubMed ID: 36647826
[TBL] [Abstract][Full Text] [Related]
5. Cancer-associated fibroblast-secreted glucosamine alters the androgen biosynthesis program in prostate cancer via HSD3B1 upregulation.
Cui D; Li J; Zhu Z; Berk M; Hardaway A; McManus J; Chung YM; Alyamani M; Valle S; Tiwari R; Han B; Goudarzi M; Willard B; Sharifi N
J Clin Invest; 2023 Apr; 133(7):. PubMed ID: 37009898
[TBL] [Abstract][Full Text] [Related]
6. HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer.
Alyamani M; Emamekhoo H; Park S; Taylor J; Almassi N; Upadhyay S; Tyler A; Berk MP; Hu B; Hwang TH; Figg WD; Peer CJ; Chien C; Koshkin VS; Mendiratta P; Grivas P; Rini B; Garcia J; Auchus RJ; Sharifi N
J Clin Invest; 2018 Aug; 128(8):3333-3340. PubMed ID: 29939161
[TBL] [Abstract][Full Text] [Related]
7. HSD3B1 and Response to a Nonsteroidal CYP17A1 Inhibitor in Castration-Resistant Prostate Cancer.
Almassi N; Reichard C; Li J; Russell C; Perry J; Ryan CJ; Friedlander T; Sharifi N
JAMA Oncol; 2018 Apr; 4(4):554-557. PubMed ID: 29049452
[TBL] [Abstract][Full Text] [Related]
8. HSD3B1 variant and androgen-deprivation therapy outcome in prostate cancer.
Han FF; Ren LL; Xuan LL; Lv YL; Liu H; Gong LL; An ZL; Liu LH
Cancer Chemother Pharmacol; 2021 Jan; 87(1):103-112. PubMed ID: 33141329
[TBL] [Abstract][Full Text] [Related]
9. Germline Variant in HSD3B1 (1245 A > C) and Response to Abiraterone Acetate Plus Prednisone in Men With New-Onset Metastatic Castration-Resistant Prostate Cancer.
Hahn AW; Gill DM; Nussenzveig RH; Poole A; Farnham J; Cannon-Albright L; Agarwal N
Clin Genitourin Cancer; 2018 Aug; 16(4):288-292. PubMed ID: 29674118
[TBL] [Abstract][Full Text] [Related]
10. Variant allele of HSD3B1 increases progression to castration-resistant prostate cancer.
Wu G; Huang S; Nastiuk KL; Li J; Gu J; Wu M; Zhang Q; Lin H; Wu D
Prostate; 2015 May; 75(7):777-782. PubMed ID: 25731771
[TBL] [Abstract][Full Text] [Related]
11. Dual targeting of androgen receptor and mTORC1 by salinomycin in prostate cancer.
Mirkheshti N; Park S; Jiang S; Cropper J; Werner SL; Song CS; Chatterjee B
Oncotarget; 2016 Sep; 7(38):62240-62254. PubMed ID: 27557496
[TBL] [Abstract][Full Text] [Related]
12. Chronic hypoxia stabilizes 3βHSD1 via autophagy suppression.
Qin L; Berk M; Chung YM; Cui D; Zhu Z; Chakraborty AA; Sharifi N
Cell Rep; 2024 Jan; 43(1):113575. PubMed ID: 38181788
[TBL] [Abstract][Full Text] [Related]
13. Germline HSD3B1 Genetics and Prostate Cancer Outcomes.
Thomas L; Sharifi N
Urology; 2020 Nov; 145():13-21. PubMed ID: 32866512
[TBL] [Abstract][Full Text] [Related]
14. Adrenal-Permissive Germline HSD3B1 Allele and Prostate Cancer Outcomes.
McKay RR; Nelson TJ; Pagadala MS; Teerlink CC; Gao A; Bryant AK; Agiri FY; Guram K; Thompson RF; Pridgen KM; Seibert TM; Lee KM; Carter H; Lynch JA; Hauger RL; Rose BS
JAMA Netw Open; 2024 Mar; 7(3):e242976. PubMed ID: 38506808
[TBL] [Abstract][Full Text] [Related]
15. HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study.
Hearn JWD; AbuAli G; Reichard CA; Reddy CA; Magi-Galluzzi C; Chang KH; Carlson R; Rangel L; Reagan K; Davis BJ; Karnes RJ; Kohli M; Tindall D; Klein EA; Sharifi N
Lancet Oncol; 2016 Oct; 17(10):1435-1444. PubMed ID: 27575027
[TBL] [Abstract][Full Text] [Related]
16. Hypoxia-Reoxygenation Couples 3βHSD1 Enzyme and Cofactor Upregulation to Facilitate Androgen Biosynthesis and Hormone Therapy Resistance in Prostate Cancer.
Qin L; Chung YM; Berk M; Naelitz B; Zhu Z; Klein E; Chakraborty AA; Sharifi N
Cancer Res; 2022 Jul; 82(13):2417-2430. PubMed ID: 35536859
[TBL] [Abstract][Full Text] [Related]
17. HSD3B1 status as a biomarker of androgen deprivation resistance and implications for prostate cancer.
Hettel D; Sharifi N
Nat Rev Urol; 2018 Mar; 15(3):191-196. PubMed ID: 29231195
[TBL] [Abstract][Full Text] [Related]
18. HSD3B1 Genotypes Conferring Adrenal-Restrictive and Adrenal-Permissive Phenotypes in Prostate Cancer and Beyond.
Sabharwal N; Sharifi N
Endocrinology; 2019 Sep; 160(9):2180-2188. PubMed ID: 31271415
[TBL] [Abstract][Full Text] [Related]
19. Abiraterone switches castration-resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling.
Moll JM; Hofland J; Teubel WJ; de Ridder CMA; Taylor AE; Graeser R; Arlt W; Jenster GW; van Weerden WM
Prostate; 2022 Apr; 82(5):505-516. PubMed ID: 35037287
[TBL] [Abstract][Full Text] [Related]
20. Association of Missense Polymorphism in HSD3B1 With Outcomes Among Men With Prostate Cancer Treated With Androgen-Deprivation Therapy or Abiraterone.
Shiota M; Narita S; Akamatsu S; Fujimoto N; Sumiyoshi T; Fujiwara M; Uchiumi T; Habuchi T; Ogawa O; Eto M
JAMA Netw Open; 2019 Feb; 2(2):e190115. PubMed ID: 30794306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
